VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, announced the engagement of PharmaVentures Ltd (“PharmaVentures”) to act as an advisor. PharmaVentures will provide strategic advice and transactional support as Volition works towards securing licensing deals with industry leaders for both Nu.Q(R) Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR(TM) – a novel detection method for liquid biopsy in cancer and potentially other diseases.
“PharmaVentures is a respected, international advisory company with a proven track record in licensing, partnering, and strategic alliances. PharmaVentures’ specialist experience in deal-making and extensive network means that it is ideally placed to support us as we seek to commercialize our potentially ground-breaking oncology and Capture PCR(TM) portfolio,” stated Gael Forterre, Chief Commercial Officer at Volition. ”We have a large amount of study data that we anticipate is close to being ready for inclusion in our data rooms and look forward to negotiating our first licensing deal in the human space.”
Adrian Dawkes, Managing Director, PharmaVentures, commented, “We believe Volition’s cutting-edge, epigenetic technology has the potential to significantly improve patient outcomes in the diagnosis and management of cancer patients and other diseases. Our role is to secure major licensing deals with key industry players and ensure Volition’s low-cost, simple blood tests are accessible worldwide. We are delighted to be supporting Volition in fulfilling its mission.”
To learn more about Volition and its technologies, please visit: www.Volition.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
